Abstract
Hepatocyte Growth Factor/Scatter Factor (HGF/SF) mediates a wide variety of cellular responses by acting through the Met tyrosine kinase receptor. Inappropriate expression of HGF/SF and/or Met has been found in most types of solid tumors and is often associated with poor prognosis. Importantly, constitutional and sporadic activating mutations in Met have been discovered in human papillary renal carcinomas and other cancers, while autocrine and paracrine signaling of this receptor/ligand pair has been shown to contribute to tumorigenesis and metastasis. Numerous downstream signaling molecules have been implicated in HGF/SF-Met mediated tumorigenesis and metastasis. Stat3 is a downstream signaling molecule activated by HGF/SF-Met signaling, and is reported to contribute to cell transformation induced by a diverse set of oncoproteins. Stat3 is constitutively activated in many primary tumors and tumor cell lines, suggesting that signaling by this molecule may be important for cell transformation. To address whether Stat3 is required for HGF/SF-Met mediated tumorigenesis and metastasis, we introduced a dominant-negative form of Stat3, Stat3β into the human leiomyosarcoma cell line SK-LMS-1. We found that Stat3β has no effect on the transformed morphology, proliferation, invasion or branching morphogenesis in vitro. By contrast, expression of Stat3β affected HGF/SF-Met mediated anchorage-independent colony formation and prevented tumorigenic growth in athymic nu/nu mice. Thus, Met signaling through Stat3 provides an essential function for tumorigenic growth, which is manifested in vitro by loss of anchorage-independent growth.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Besser D, Bromberg JF, Darnell Jr JE, Hanafusa H . 1999 Mol. Cell. Biol. 19: 1401–1409
Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C . 1995 Nature 376: 768–771
Boccaccio C, Ando M, Tamagnone L, Bardelli A, Michieli P, Battistini C, Comoglio PM . 1998 Nature 391: 285–288
Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA . 1991 Science 251: 802–804
Bowman T, Garcia R, Turkson J, Jove R . 2000 Oncogene 19: 2474–2488
Bromberg JF, Darnell Jr JE . 2000 Oncogene 19: 2468–2473
Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell Jr JE . 1998 Mol. Cell. Biol. 18: 2553–2558
Bussolino F, Di RM, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM . 1992 J. Cell Biol. 119: 629–641
Caldenhoven E, van Dijk TB, Solari R, Armstrong J, Raaijmakers JAM, Lammers JWJ, Koenderman L, de Groot RP . 1996 J. Biol. Chem. 271: 13221–13227
Cortner J, Vande Woude GF, Rong S . 1995 The Met-HGF/SF autocrine signaling mechanism is involved in sarcomogenesis Basel/Switzerland: Birkhauser Verlag
Decker T, Kovarik P . 2000 Oncogene 19: 2628–2637
Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD, Valente G, Giordano S, Cortesina G, Comoglio PM . 2000 Oncogene 19: 1547–1555
Faletto DL, Kaplan DR, Halverson DO, Rosen EM, Vande Woude GF . 1993 EXS 65: 107–130
Fan S, Ma YX, Wang JA, Yuan RQ, Meng Q, Cao Y, Laterra JJ, Goldberg ID, Rosen EM . 2000 Oncogene 19: 2212–2223
Fixman ED, Fournier TM, Kamikura DM, Naujokas MA, Park M . 1996 J. Bio. Chem. 271: 13116–13122
Gherardi E, Stoker M . 1991 Cancer Cells 3: 227–232
Giordano S, Di RM, Narsimhan RP, Tamagnone L, Gerbaudo EV, Chiado-Piat L, Comoglio PM . 1988 J Cell Biochem. 38: 229–236
Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickloff BJ, Kinsella JL, Polverini P, Rosen EM . 1993 Proc. Natl. Acad. Sci. USA 90: 1937–1941
Graziani A, Gramaglia D, Cantley LC, Comoglio PM . 1991 J. Biol. Chem. 266: 22087–22090
Jakubczak JL, LaRochelle WJ, Merlino G . 1998 Mol. Cell. Biol. 18: 1275–1283
Jeffers M, Fiscella M, Webb CP, Anver M, Koochekpour S, Vande Woude GF . 1998 Proc. Natl. Acad. Sci. USA 95: 14417–14422
Jeffers M, Rong S, Vande Woude GF . 1996 Mol. Cell. Biol. 16: 1115–1125
Khwaja A, Lehmann K, Marte BM, Downward J . 1998 J. Biol. Chem. 273: 18793–18801
Koochekpour S, Jeffers M, Rulong S, Klineberg E, Taylor G, Hudson EA, Resau JH, Vande Woude GF . 1997 Cancer Res. 57: 5391–5398
Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, Schmidt L, Zbar B, Vande Woude GF . 2000 Oncogene 19: 4947–4953
Maina F, Hilton MC, Ponzetto C, Davies AM, Klein R . 1997 Genes Dev. 11: 3341–3350
Matsumoto K, Nakamura T . 1993 Hepatocyte Growth Factor-Scatter Factor and the Met Receptor Vol. 65: Goldberg, I.D. and Rosen, E.M. (eds) Basel, Switzerland: Birkhauser-Verlag pp. 225–250
Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, Dalton W, Jove R, Yu H . 1999 Cancer Res. 59: 5059–5063
Nusrat A, Parkos CA, Bacarra AE, Godowski PJ, Delp-Archer C, Rosen EM, Madara JL . 1994 J. Clin. Invest. 93: 2056–2065
Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, Kim BJ, Bae JH, Hong YK, Lee KS, Lee SH, Yoo NJ, Jang JJ, Park S, Zhuang Z, Schmidt L, Zbar B, Lee JY . 1999 Cancer Res. 59: 307–310
Pelicci G, Giordano S, Zhen Z, Salcini AE, Lanfrancone L, Bardelli A, Panayotou G, Waterfield MD, Ponzetto C, Pelicci PG, Comoglio PM . 1995 Oncogene 10: 1631–1638
Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, Graziani A, Panayotou G, Comoglio PM . 1994 Cell 77: 261–271
Rahimi N, Hung W, Tremblay E, Saulnier R, Elliott B . 1998 J. Biol. Chem. 273: 33714–33721
Reddy EP, Korapati A, Chaturvedi P, Rane S . 2000 Oncogene 19: 2532–2547
Redley AJ, Comoglio PM, Hall A . 1995 Mol. Cell. Biol. 15: 1110–1122
Rodrigues GA, Park M, Schlessinger J . 1997 EMBO J. 16: 2634–2645
Rong S, Bodescot M, Blair D, Dunn J, Nakamura T, Mizuno K, Park M, Chan A, Aaronson S, Vande Woude GF . 1992 Mol. Cell. Biol. 12: 5152–5158
Rong S, Jeffers M, Resau JH, Tsarfaty I, Oskarsson M, Vande Woude GF . 1993 Cancer Res. 53: 5355–5360
Rong S, Segal S, Anver M, Resau JH, Vande Woude GF . 1994 Proc. Natl. Acad. Sci. USA 91: 4731–4735
Royal I, Lamarche-Vane N, Lamorte L, Kaibuchi K, Park M . 2000 Mol. Cell. Biol. 11: 1709–1725
Sano S, Itami S, Takeda K, Tarutani M, Yamaguchi Y, Miura H, Yoshikawa K, Akira S, Takeda J . 1999 EMBO J. 18: 4657–4668
Santoro MM, Collesi C, Grasend S, Gaudino G, Comoglio PM . 1996 Mol. Cell. Biol. 16: 7072–7083
Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschiesche W, Sharpe M, Gherardi E, Birchmeier C . 1995 Nature (London) 373: 699–702
Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allilmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJM, Walter MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B . 1997 Nat. Genet. 16: 68–73
Sonnenberg E, Meyer D, Weidner KM, Birchmeier C . 1993 J. Cell Biol. 123: 223–235
Southern PJ, Berg P . 1982 J. Mol. Appl. Genet. 1: 327–341
Stoker M, Gherardi E, Perryman M, Gray J . 1987 Nature (London) 327: 239–242
Streit A, Stern CD, Thery C, Ireland GW, Aparicio S, Sharpe MJ, Gherardi E . 1995 Development 121: 813–824
Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, Aaronson SA, Merlino G . 1997 Proc. Natl. Acad. Sci. USA 94: 701–706
Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R . 1998 Mol. Cell. Biol. 18: 2545–2552
Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, Sekharam M, Frank DA, Holzman LB, Wu J, Sebti S, Jove R . 1999 Mol. Cell. Biol. 19: 7519–7528
Uehara Y, Minowa O, Mori C, Shiota K, Kuno J, Noda T, Kitamura N . 1995 Nature (London) 373: 702–705
Vande Woude GF, Jeffers M, Cortner J, Alvord G, Tsarfaty I, Resau J . 1997 CIBA Found. Symp.: Plasminogen-Related Growth Factors Vol. 212: Bock GR and Goode JA (eds) West Sussex: John Wiley & Sons Ltd pp. 119–132
Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM . 2001 J. Cell Biol. 153: 1023–1033
Weidner KM, Di Cesare S, Sachs M, Brinkmann V, Behrens J, Birchmeier W . 1996 Nature 384: 173–176
Weidner KM, Sachs M, Birchmeier W . 1993 J. Cell Biol. 121: 145–154
Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF, Testa JR . 2001 Proc. Natl. Acad. Sci. USA 98: 247–252
Zong CS, Zeng L, Jiang Y, Sadowski HB, Wang LH . 1998 J. Biol. Chem. 273: 28065–28072
Acknowledgements
We thank Brian Cao for providing anti-HGF/SF neutralizing antibody, James Resau and Eric Hudson for confocal microscope images, Dawna Dylewski, Jason Martin and Bryn Eagleson for helping on the animal study (Van Andel Research Institute). We thank the Van Andel Institute for their financial support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, YW., Wang, LM., Jove, R. et al. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene 21, 217–226 (2002). https://doi.org/10.1038/sj.onc.1205004
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205004
Keywords
This article is cited by
-
Translation of circHGF RNA encodes an HGF protein variant promoting glioblastoma growth through stimulation of c-MET
Journal of Neuro-Oncology (2023)
-
Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic drivers
Journal of Experimental & Clinical Cancer Research (2022)
-
Loss of USP28 and SPINT2 expression promotes cancer cell survival after whole genome doubling
Cellular Oncology (2022)
-
MET targeting: time for a rematch
Oncogene (2020)
-
Stat2 stability regulation: an intersection between immunity and carcinogenesis
Experimental & Molecular Medicine (2020)